The RFS benefit of adjuvant pembrolizumab given for high-risk stage II #melanoma persists even after accounting for new melanoma diagnoses. Published in @jamanetworkopen.com.

https://bit.ly/4kUR9xH

#melcsm #skcsm

14% of adults under 35 believe sunscreen is riskier than UV exposure. Clinical intervention is required to counter this trend.

☀️ SPF 15+ reduces melanoma risk by 50% ☀️ UV is a proven human carcinogen

Read the review: https://bit.ly/46g3OF9

#skcsm #melcsm #nosunscreen

Anticoagulation Therapies May Improve Survival in Advanced BRAF-Mutant Melanoma - Oncology Nurse Advisor Investigators assessed whether anticoagulation and platelet aggregation inhibition could have antitumoral effects when used along side targeted therapies for patients with unresectable stage III-IV BRAF-mutant melanoma.

Patients with advanced #melanoma who received anticoagulation therapy, particularly direct oral anticoagulants (DOACs), saw improvements in survival. Published in @cancertherapyadv.bsky.social.

https://bit.ly/469nAlL

#melcsm #skcsm

Toripalimab Bests Dacarbazine as First-Line Treatment for Advanced Melanoma Investigators evaluated the efficacy and safety of toripalimab versus dacarbazine as the first-line treatment in advanced melanoma predominantly of acral subtype.

Toripalimab improves PFS compared with dacarbazine for treatment-naïve patients with advanced #melanoma, including acral melanoma. Published in @jamaoncology.com.

https://bit.ly/4a2vIH0

#melcsm

Use of Tanning Beds More Than Doubles Melanoma Risk Use of tanning beds more than doubles the risk of developing melanoma by increasing the mutation burden in melanocytes, including at skin sites with

Use of tanning beds more than doubles the risk of developing #melanoma by increasing the mutation burden in melanocytes, including at skin sites with ordinarily low cumulative sun exposure. Published in @science.org.

https://bit.ly/4ja8yBJ

#melcsm

Metastatic Melanoma Survival Worse in Hispanic Patients Than Non-Hispanic Patients - Oncology Nurse Advisor In this study, researchers explored disparities in metastatic cutaneous melanoma survival following the introduction of immunotherapies.

Hispanic patients with metastatic cutaneous #melanoma have worse survival outcomes than non-Hispanic patients.

https://bit.ly/4pSrGqw

#melcsm

Higher Melanoma Incidence Seen in Agriculturally Intensive Counties In the study, researchers evaluated county-level data across Pennsylvania for variables such as melanoma incidence, agricultural land use, agrochemical-treated acreage, ambient ultraviolet radiation, and social vulnerability.

Researchers have identified higher #melanoma incidence in an agriculturally intensive region of south central Pennsylvania compared to other parts of the state. Published in @ascopost.bsky.social.

https://bit.ly/48hj98K

#melcsm

The IFNγ-CIITA-MHC II axis modulates melanoma cell susceptibility to NK-cell-mediated cytotoxicity

👉 buff.ly/tJzVEhb

#Melanoma #MELCSM #ImmunoOnc

Rule Out Melanoma Terminology on Pathology Requisitions Has Low Predictive Value - Oncology Nurse Advisor Researchers studied the diagnostic yield associated with rule of melanoma terminology used on skin biopsy requisition forms.

The use of rule out #melanoma terminology on pathology requisitions has a low positive predictive value for the diagnosis of melanoma. Published in @dermatologyadvisor.bsky.social.

https://bit.ly/4oHtCRr

#melcsm #skcsm

Novel STAT3 Inhibitor TT1-101 Is Safe and Shows Antitumor Activity in R/R HCC and Other Solid Tumors The STAT3 inhibitor TT1-101 generated confirmed partial responses among patients with relapsed/refractory HCC and other solid tumors.

Novel STAT3 Inhibitor TT1-101 Is Safe and Shows Antitumor Activity in R/R HCC and Other Solid Tumors #gyncsm #melcsm #lcsm #oncology
www.onclive.com/view/novel-s...